1.31
price up icon3.97%   0.05
after-market After Hours: 1.37 0.06 +4.58%
loading
Adicet Bio Inc stock is traded at $1.31, with a volume of 499.55K. It is up +3.97% in the last 24 hours and down -7.75% over the past month. Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$1.26
Open:
$1.26
24h Volume:
499.55K
Relative Volume:
1.38
Market Cap:
$107.95M
Revenue:
$38.70M
Net Income/Loss:
$-142.66M
P/E Ratio:
-0.4816
EPS:
-2.72
Net Cash Flow:
$-98.18M
1W Performance:
-7.09%
1M Performance:
-7.75%
6M Performance:
-9.66%
1Y Performance:
-20.61%
1-Day Range:
Value
$1.25
$1.39
1-Week Range:
Value
$1.20
$1.43
52-Week Range:
Value
$1.05
$3.77

Adicet Bio Inc Stock (ACET) Company Profile

Name
Name
Adicet Bio Inc
Name
Phone
617-482-2333
Name
Address
131 DARTMOUTH STREET, BOSTON
Name
Employee
143
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
ACET's Discussions on Twitter

Adicet Bio Inc Stock (ACET) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-27-23 Downgrade Guggenheim Buy → Neutral
Jun-27-23 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-01-23 Downgrade JP Morgan Overweight → Neutral
Sep-21-22 Initiated JP Morgan Overweight
Mar-31-22 Initiated SMBC Nikko Outperform
Mar-08-22 Initiated Truist Buy
Mar-04-22 Initiated Jefferies Buy
May-18-21 Initiated BTIG Research Buy
Apr-23-21 Initiated H.C. Wainwright Buy
Apr-14-21 Initiated Canaccord Genuity Buy
Apr-08-21 Initiated Guggenheim Buy
Nov-04-20 Initiated B. Riley Securities Buy
Oct-27-20 Initiated JMP Securities Mkt Outperform
Oct-16-20 Initiated Wedbush Outperform
View All

Adicet Bio Inc Stock (ACET) Latest News

pulisher
07:00 AM

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - StockTitan

07:00 AM
pulisher
Nov 01, 2024

Adicet Bio to Participate in Upcoming Investor Conferences - StockTitan

Nov 01, 2024
pulisher
Oct 31, 2024

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Oct 31, 2024
pulisher
Oct 18, 2024

HC Wainwright Reiterates Neutral Rating for Adicet Bio (NASDAQ:ACET) - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Adicet Bio shares maintain Neutral rating after FDA IND amendment - Investing.com India

Oct 17, 2024
pulisher
Oct 17, 2024

Adicet Bio shares maintain Neutral rating after FDA IND amendment By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

FDA greenlights Adicet Bio's trial expansion for autoimmune diseases - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome - StockTitan

Oct 16, 2024
pulisher
Oct 15, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Down 11.0% in September - MarketBeat

Oct 15, 2024
pulisher
Oct 13, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Cubist Systematic Strategies LLC - MarketBeat

Oct 13, 2024
pulisher
Oct 08, 2024

Adicet Bio (NASDAQ:ACET) Raised to "Hold" at StockNews.com - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Millennium Management LLC Adjusts Stake in Adicet Bio Inc - GuruFocus.com

Oct 08, 2024
pulisher
Oct 04, 2024

Renaissance Technologies LLC Has $1.83 Million Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Adicet Bio Inc’s Shares Reel: 36.70% Quarterly Revenue Decline Amid 122.78M Market Cap - The InvestChronicle

Oct 03, 2024
pulisher
Oct 03, 2024

Did Adicet Bio Inc (ACET) perform well in the last session? - US Post News

Oct 03, 2024
pulisher
Oct 03, 2024

Adicet Bio, Inc.'s (NASDAQ:ACET) large institutional owners must be happy as stock continues to impress, up 11% over the past week - Simply Wall St

Oct 03, 2024
pulisher
Oct 02, 2024

Recent Insider Activity Suggests Potential Gains for Adicet Bio Inc (ACET) - Knox Daily

Oct 02, 2024
pulisher
Oct 01, 2024

Adicet Bio stock maintains neutral rating amid lupus nephritis trial - Investing.com

Oct 01, 2024
pulisher
Oct 01, 2024

Stonepine Capital Management LLC Has $737,000 Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy - Clinical Trials Arena

Oct 01, 2024
pulisher
Oct 01, 2024

Stonepine Capital Management LLC Increases Stake in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference - Business Wire

Sep 30, 2024
pulisher
Sep 30, 2024

Adicet Bio (NASDAQ:ACET) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Guggenheim - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Guggenheim Begins Coverage on Adicet Bio (NASDAQ:ACET) - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases - BioSpace

Sep 30, 2024
pulisher
Sep 30, 2024

Adicet Bio Launches Phase 1 Trial of ADI-001, Eyes Expansion - TipRanks

Sep 30, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Adicet Bio stock navigates competitive CAR-T waters - Investing.com

Sep 27, 2024
pulisher
Sep 25, 2024

Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive™

Sep 25, 2024
pulisher
Sep 24, 2024

Analysts’ Weekly Ratings Changes for Adicet Bio (ACET) - Defense World

Sep 24, 2024
pulisher
Sep 21, 2024

Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa

Sep 21, 2024
pulisher
Sep 20, 2024

Adicet Bio shares hold neutral rating amid positive study data - Investing.com

Sep 20, 2024
pulisher
Sep 20, 2024

Adicet Bio (NASDAQ:ACET) Earns Outperform Rating from Wedbush - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

Adicet Bio reports promising ADI-001 therapy data - Investing.com

Sep 20, 2024
pulisher
Sep 19, 2024

HC Wainwright Reiterates "Neutral" Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat

Sep 19, 2024
pulisher
Sep 19, 2024

Adicet Bio reports promising ADI-001 therapy data By Investing.com - Investing.com Australia

Sep 19, 2024
pulisher
Sep 19, 2024

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue - BioSpace

Sep 19, 2024
pulisher
Sep 17, 2024

Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Declines By 10.3% - MarketBeat

Sep 17, 2024
pulisher
Sep 16, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Acadian Asset Management LLC - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Shares Purchased by Acadian Asset Management LLC - Defense World

Sep 16, 2024
pulisher
Sep 14, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Expected to Earn FY2026 Earnings of ($1.11) Per Share - Defense World

Sep 14, 2024
pulisher
Sep 13, 2024

Insider Selling: Kauffman Michael, Adicet Bio Inc [ACET] Director divested 5,900 shares - Knox Daily

Sep 13, 2024
pulisher
Sep 13, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Forecasted to Post FY2026 Earnings of ($1.11) Per Share - MarketBeat

Sep 13, 2024
pulisher
Sep 13, 2024

ACET’s Stock Market Adventure: -19.05% YTD Growth Amidst Volatility - The InvestChronicle

Sep 13, 2024
pulisher
Sep 13, 2024

Check Out Adicet Bio Inc (ACET)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 13, 2024
pulisher
Sep 12, 2024

Adicet Bio (NASDAQ:ACET) Given New $8.00 Price Target at Canaccord Genuity Group - Defense World

Sep 12, 2024
pulisher
Sep 12, 2024

Adicet Bio stock target cut by Canaccord Genuity on adjusted expectations - Investing.com

Sep 12, 2024

Adicet Bio Inc Stock (ACET) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Adicet Bio Inc Stock (ACET) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
ORBIMED ADVISORS LLC
Director
Jan 25 '24
Buy
2.40
3,125,000
7,500,000
7,526,359
GORDON CARL L
Director
Jan 25 '24
Buy
2.40
3,125,000
7,500,000
7,526,359
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):